Form 4: Vericel Corp Executive Jonathan Siegal Reports Stock Transactions
SEC Form 4
Principal Accounting Officer Jonathan Siegal of Vericel Corp reports exercising stock options and selling shares under a pre-arranged trading plan.
Summary
- On February 5, 2025, Jonathan Siegal, Principal Accounting Officer of Vericel Corp, executed transactions involving the company's stock.
- Siegal exercised stock options to acquire 1,092 shares of common stock at a price of $48.80.
- Simultaneously, Siegal sold 1,092 shares of common stock at a price of $61.99.
- These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2024.
- Following these transactions, Siegal directly owns 1,206 shares of Vericel Corp common stock.
- Siegal also holds options to purchase 51,875 shares of common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan, with no indication of positive or negative outlook.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders, providing transparency into their transactions in company stock. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the financial industry.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals are also subject to similar insider trading regulations and reporting requirements.
- The use of Rule 10b5-1 trading plans is a standard method for insiders to manage their stock transactions while avoiding accusations of trading on non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 2022-09-30 | Options became exercisable, with 25% vesting initially. |
| 2024-03-13 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-02-05 | Date of stock option exercise and sale of shares. |
| 2025-02-07 | Date of signature of the Form 4 filing. |
| 2031-09-30 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.